News, Announcements and Expert Commentary from Inova

Posts Tagged ‘schar’

FDA Approves Cutting-Edge Cancer Drug from Inova Schar Cancer Institute Clinical Trial

dart board with a red dart in the center bulls eye

Inova’s Dr. John Deeken served as the site principal investigator for this prestigious study In groundbreaking news for the medical and cancer research community, the Food and Drug Administration (FDA) approved a new, breakthrough cancer drug, larotrectinib, or Vitrakvi®, that targets specific genetic mutations in adult and pediatric patients. This is only the second tissue-agnostic…

Read More

From Research to Results: Advances in Genitourinary Cancer Treatment  

Jeanny B. Aragon-Ching, MD, is the clinical program director of genitourinary cancers at the Inova Schar Cancer Institute. She is board certified in medical oncology, hematology and internal medicine and has a special interest in caring for patients with prostate, bladder, kidney and testicular cancers. Read Dr. Aragon-Ching’s profile.  This February, I’ll be traveling to…

Read More